The mechanism by which NF1 loss abrogates ERK to RAF feedback in neuroblastoma cells harboring ALK mutations remains elusive, but this will not prevent a rapid translation of this collateral sensitivity into the clinic. This evidence concerns the gene ALK and neuroblastoma.